Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
Alimentary Pharmacology and Therapeutics, Volume 28, No. 5, Year 2008
Notification
URL copied to clipboard!
Description
Background: Nitazoxanide, licensed in the US for treatment of Cryptosporidium parvum and Giardia lamblia, inhibits hepatitis C virus replication in replicon systems. Aim: To evaluate the safety and efficacy of nitazoxanide monotherapy for the treatment of chronic hepatitis C. Methods: This multicentre, randomized, double-blind, placebo-controlled study randomized 50 adult patients with chronic hepatitis C genotype 4 at three centres in Egypt to nitazoxanide 500 mg tablet or placebo twice daily for 24 weeks. Patients were followed up every 4 weeks during treatment and for 24 weeks after therapy. Results: Seven of 23 patients (30.4%) in the nitazoxanide group achieved undetectable serum HCV RNA compared to 0 of 24 in the placebo group during therapy (P = 0.004). Each of the seven responders had baseline HCV RNA levels ≤400 000 IU/mL. Six of the seven virological responders were followed up for 24 weeks after the end of treatment, and four patients (17.4% of 23 treated) had a sustained virological response. Adverse events were similar in the nitazoxanide and placebo groups. Conclusion: Nitazoxanide monotherapy is safe and effective in achieving sustained virological response in a modest number of patients with chronic hepatitis C genotype 4, particularly in patients with low baseline serum HCV RNA levels. © 2008 The Authors.
Authors & Co-Authors
Rossignol, Jean François A.
United States, Tampa
Romark Institute for Medical Research
United States, Stanford
Stanford University School of Medicine
Kabil, Samir M.
Egypt, Benha
Faculty of Medicine
El-Gohary, Yehia M.
Egypt, Alexandria
Faculty of Medicine
Elfert, Asem Ahmed
Egypt, Tanta
Faculty of Medicine
Keeffe, Emmet B.
United States, Tampa
Romark Institute for Medical Research
United States, Stanford
Stanford University School of Medicine
Statistics
Citations: 77
Authors: 5
Affiliations: 5
Identifiers
Doi:
10.1111/j.1365-2036.2008.03781.x
ISSN:
02692813
e-ISSN:
13652036
Research Areas
Disability
Genetics And Genomics
Infectious Diseases
Study Locations
Egypt